Premium
Compatibility Test Using 51 Chromium‐Labeled Red Blood Cells in Crossmatch Positive Patients
Author(s) -
Silvergleid A. J.,
Wells R. F.,
Hafleigh E. B.,
Korn G.,
Kellner J. J.,
Grumet F. C.
Publication year - 1978
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1046/j.1537-2995.1978.18178118571.x
Subject(s) - medicine , antibody , antigen , in vivo , hematocrit , immunology , autoantibody , hemolytic anemia , gastroenterology , biology , microbiology and biotechnology
For the past three years, we have routinely used the one‐hour in vivo survival of 51 Cr‐labeled donor red blood cells to select units for transfusion to patients for whom crossmatch compatible blood was unavailable. This technique successfully evaluated in vivo compatibility, thus avoiding acute hemolytic transfusion reactions in 38 problem patients. New or confirmatory data regarding the hemolytic potential of several well defined antibodies was also obtained. Antibodies which proved to be clinically insignificant included: anti‐I T (all IgG), anti‐Sd a , anti‐Kir, Mil, Oca, anti‐Chido, anti‐Bg, 14 of 15 “nonspecific warm autoantibodies” (three of which were associated with the ingestion of alphamethyldopa), and four of five antibodies to high‐incidence antigens. Clinically significant antibodies included: anti‐Yt a , anti‐Jk b , the antibody in PCH (with “P” specificity), one intensely hemolytic “nonspecific warm autoagglutinin,” and one of five incompletely characterized antibodies to high‐incidence antigens. An acceptable in vivo compatibility test in every instance was associated with an appropriate rise in hematocrit and no clinical symptoms of hemolytic transfusion reaction.